Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday, Zacks.com reports. The firm currently has a $27.00 target price on the stock. Zacks Investment Research‘s target price suggests a potential upside of 19.89% from the company’s current price.
According to Zacks, “Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company’s lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative breast cancer which is in clinical stage. It operates principally in New York and San Diego. Zentalis Pharmaceuticals, Inc. is based in NEW YORK. “
Other analysts also recently issued reports about the company. Oppenheimer decreased their price target on Zentalis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Tuesday, April 12th. Wells Fargo & Company assumed coverage on Zentalis Pharmaceuticals in a research note on Wednesday, April 6th. They issued an “overweight” rating and a $67.00 price target on the stock. SVB Leerink decreased their price target on Zentalis Pharmaceuticals from $78.00 to $67.00 and set an “outperform” rating on the stock in a research note on Tuesday, April 12th. Stifel Nicolaus decreased their target price on Zentalis Pharmaceuticals from $94.00 to $74.00 in a research report on Monday, April 11th. Finally, Guggenheim decreased their target price on Zentalis Pharmaceuticals from $92.00 to $67.00 in a research report on Wednesday, April 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals presently has an average rating of “Buy” and an average target price of $76.33.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last announced its earnings results on Thursday, February 24th. The company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.23. During the same period in the previous year, the company earned ($1.01) earnings per share. Research analysts expect that Zentalis Pharmaceuticals will post -5.03 EPS for the current year.
In other news, SVP Dimitris Voliotis sold 601 shares of the company’s stock in a transaction on Monday, February 14th. The stock was sold at an average price of $50.23, for a total value of $30,188.23. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Alexis Pinto sold 691 shares of the company’s stock in a transaction on Monday, February 14th. The shares were sold at an average price of $50.23, for a total value of $34,708.93. The disclosure for this sale can be found here. Insiders sold 153,307 shares of company stock worth $7,527,251 over the last 90 days. Company insiders own 21.00% of the company’s stock.
Large investors have recently made changes to their positions in the business. Schonfeld Strategic Advisors LLC increased its stake in Zentalis Pharmaceuticals by 40.6% during the third quarter. Schonfeld Strategic Advisors LLC now owns 29,287 shares of the company’s stock worth $1,952,000 after acquiring an additional 8,451 shares during the last quarter. TD Asset Management Inc. increased its stake in Zentalis Pharmaceuticals by 11.3% during the third quarter. TD Asset Management Inc. now owns 91,258 shares of the company’s stock worth $6,081,000 after acquiring an additional 9,292 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in Zentalis Pharmaceuticals during the fourth quarter worth about $464,000. Deutsche Bank AG increased its stake in Zentalis Pharmaceuticals by 51.1% during the third quarter. Deutsche Bank AG now owns 33,803 shares of the company’s stock worth $2,253,000 after acquiring an additional 11,438 shares during the last quarter. Finally, Voloridge Investment Management LLC increased its stake in Zentalis Pharmaceuticals by 74.5% during the third quarter. Voloridge Investment Management LLC now owns 47,322 shares of the company’s stock worth $3,154,000 after acquiring an additional 20,208 shares during the last quarter. Institutional investors own 94.61% of the company’s stock.
About Zentalis Pharmaceuticals (Get Rating)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.